Remove 2023 Remove Hypertension Remove Pulmonary
article thumbnail

Unique Cell-based Approach for Pulmonary Arterial Hypertension Shown to Be Safe

DAIC

Pulmonary arterial hypertension, a form of high blood pressure that occurs in the lungs, is a target of research by Cedars-Sinai investigators. Pulmonary arterial hypertension is a rare disease, affecting fewer than 100 people per million. Siegel Family Foundation Distinguished Professor and senior author of the study. “We

Pulmonary 105
article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Clinical characteristics and mortality risk factors in pediatric hypertrophic, restrictive, and rapidly progressive hypertrophic cardiomyopathy: a retrospective cohort study with follow-up

Frontiers in Cardiovascular Medicine

The independent risk factors for mortality included left ventricular ejection fraction (LVEF), pulmonary hypertension, and low-density lipoprotein (LDL) levels (P<0.05). LVEF, pulmonary hypertension, and LDL levels are critical prognostic factors, offering insights for risk assessment and management in affected children.

article thumbnail

Noninvasive evaluation of pulmonary hypertension using the second heart sound parameters collected by a mobile cardiac acoustic monitoring system

Frontiers in Cardiovascular Medicine

Background Pulmonary hypertension (PH) is linked to higher rates of morbidity and mortality worldwide. The estimated pulmonary artery systolic pressure (ePASP ≥ 35 mmHg) measured by echocardiography helps screen PH patients. Early diagnosis of PH is important for clinical treatment.

article thumbnail

Differential effects of balloon pulmonary angioplasty on chronic thromboembolic pulmonary disease

Heart BMJ

Background Decreased diffusing capacity of the lungs for carbon monoxide (DLco) is associated with microvascular damage in chronic thromboembolic pulmonary hypertension (CTEPH). However, low DLco may attenuate the effect of BPA on mPAP and pulmonary vascular resistance and require more treatment sessions. mm Hg) before BPA.

article thumbnail

Omics and Extreme Phenotyping Reveal Longitudinal Association Between Left Atrial Size and Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension

Journal of the American Heart Association

Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. BackgroundLeft heart disease is the most common cause of pulmonary hypertension (PH) and is frequently accompanied by increases in pulmonary vascular resistance.

article thumbnail

Transpulmonary Expression of Exosomal microRNAs in Idiopathic and Congenital Heart Disease–Related Pulmonary Arterial Hypertension

Journal of the American Heart Association

Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. BackgroundPulmonary artery hypertension (PAH) is a fatal disease characterized by a complex pathogenesis. Transpulmonary exosomal miRs offer valuable insights into pulmonary circulation microenvironments.